Precipio Commences Validation Study Of Proprietary IV-Cell Cytogenetics Media At University Of Pennsylvania

NEW HAVEN, CT, (January 22nd, 2018) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), today announced it [...]

Precipio Appoints New Sales VP To Manage Diagnostics Sales Expansion

Sales growth acceleration plan to triple size of oncologist/hospital sales team in 2018 NEW HAVEN, [...]

Yale Study Demonstrates Four-Fold Superiority Of Academic Level Diagnostic Accuracy

Study further shows ~73% of cases which academic pathologists determined were previously misdiagnosed, have definite [...]